Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis
- Ronit Gurion
- , Anat Gafter-Gvili
- , Liat Vidal
- , Avi Leader
- , Ron Ram
- , Adi Shacham-Abulafia
- , Mical Paul
- , Isaac Ben-Bassat
- , Ofer Shpilberg
- , Pia Raanani
Research output: Contribution to journal › Review article › peer-review
29
Scopus
citations